← Back to headlines
Kyverna Reports Positive Mid-Stage Trial Data for Myasthenia Gravis Therapy
Kyverna's stock rose following the release of new mid-stage trial data for its myasthenia gravis therapy.
20 Apr, 18:15 — 20 Apr, 18:15
Sources
Showing 1 of 1 sources
Related Stories
'Astronauts back on Earth': Artemis II crew splashes down after record-breaking moon flyby – video
just now
BridgeBio Oncology rises on Fast Track status for pancreatic cancer asset
47m ago
Spectacular Video Shared from Moon Mission
52m ago
Breakthrough Therapy Shows Promise Against Pancreatic Cancer
59m ago